Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Kits > TNFSF11 > EP-145

TNFSF11 : Osteoprotegerin Inhibitor Screening ELISA Kit

For research use only.

Order Now

EP145-C01High-bind Plate1 plate
EP145-C02Human TNFSF1115 μg
EP145-C03HRP-Human Osteoprotegerin10 μg
EP145-C04Anti-TNFSF11 Neutralizing Antibody20 μg
EP145-C05Coating Buffer12 mL
EP145-C0610xWashing Buffer 50 mL
EP145-C07Blocking Buffer50 mL
EP145-C08Substrate Solution12 mL
EP145-C09Stop Solution7 mL
  • Background
    Receptor activator of nuclear factor kappa-B ligand (RANKL), also known as tumor necrosis factor ligand superfamily member 11 (TNFSF11), TNF-related activation-induced cytokine (TRANCE), osteoprotegerin ligand (OPGL), and osteoclast differentiation factor (ODF), is known as a type II membrane protein and is a member of the tumor necrosis factor (TNF) superfamily. RANKL, through its ability to stimulate osteoclast formation and activity, is a critical mediator of bone resorption and overall bone density. Some findings also suggestion some cancer cells, particularly prostate cancer cells, can activate an increase in bone remodeling and ultimately increase overall bone production. This increase in bone remodeling and bone production increases the overall growth of bone metastasizes. The overall control of bone remodeling is regulated by the binding of RANKL with its receptor or its decoy receptor, respectively, RANK and OPG.
  • Application
    This kit is developed for screening for inhibitors of human TNFSF11 binding to human Osteoprotegerin.

    It is for research use only.

  • Reconstitution
    Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
  • Storage
    The unopened kit is stable for 12 months from the date of manufacture if stored at 2°C to 8°C.

    The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.

  • Assay Principles
    This inhibitor screening ELISA kit is designed to facilitate the identification and characterization of new TNFSF11 pathway inhibitors. The assay takes advantage of our in house-developed binding of human Osteoprotegerin to immobilized human TNFSF11 in a functional ELISA assay, and employs a simple colorimetric ELISA platform. Briefly, we provide you with a human Osteoprotegerin, a human TNFSF11 protein, an anti-TNFSF11 neutralizing antibody (as method verified Std.).

    Your experiment will include 4 simple steps:

    a) Coat the plate with human TNFSF11.

    b) Add your molecule of interest to the tests.

    c) Add human Osteoprotegerin to bind the coated TNFSF11.

    d) Add TMB or other colorimetric HRP substrate.

    Finally, the half maximal inhibitory concentration (IC50) of your compound to TNFSF11: Osteoprotegerin binding will be determined by comparing OD readings among different experimental groups.

Typical Data Please refer to DS document for The assay protocol.

Serial dilutions of Anti-TNFSF11 Neutralizing antibody (Catalog # EP145-C04) (1:1 serial dilution, from 20 μg/mL to 0.01μg/mL) was added into TNFSF11: Osteoprotegerin binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).

Comments (0)

ETD of in-stock products: 2 business days

Price(USD) : $650.00

Promotion & Exhibitions

Drug Development Status

  • Number of Launched Drugs:3 Details
  • Number of Drugs in Clinical Trials:27 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message